AbbVie
ABBV
#32
Rank
C$447.41 B
Marketcap
$253.19
Share price
0.23%
Change (1 day)
15.18%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

P/E ratio for AbbVie (ABBV)

P/E ratio as of January 2025 (TTM): 47.6

According to AbbVie's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 47.6166. At the end of 2022 the company had a P/E ratio of 24.3.

P/E ratio history for AbbVie from 2012 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202224.316.29%
202120.9-43.89%
202037.2122.84%
201916.7-35.26%
201825.8-11.41%
201729.170.28%
201617.1-8.47%
201518.7-68.3%
201458.9188.94%
201320.492.03%
201210.6

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
14.3-69.94%๐Ÿ‡บ๐Ÿ‡ธ USA
14.9-68.76%๐Ÿ‡บ๐Ÿ‡ธ USA
148 211.03%๐Ÿ‡บ๐Ÿ‡ธ USA
19.9-58.19%๐Ÿ‡บ๐Ÿ‡ธ USA
21.8-54.27%๐Ÿ‡บ๐Ÿ‡ธ USA
7.82-83.57%๐Ÿ‡บ๐Ÿ‡ธ USA
10.0-78.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
35.4-25.68%๐Ÿ‡ฌ๐Ÿ‡ง UK
76.9 61.45%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.